More Big Pharma Players Have Access Plans For Poorer Countries

GSK Tops Access to Medicine Index Again

01 Feb 2021

The notion that pharma R&D caters for western populations first and only much later are the fruits of that research made available for low-income countries is slowly but surely changing, according to a high-profile review of access to drugs.

R&D access plans can bridge the healthcare gap between rich and poor • Source: Shutterstock

Pharmaceutical companies "continue to inch forward" when it comes to embedding access to new drugs in low- and middle-income countries into their governance structures, R&D processes and monitoring efforts, according to the latest report from the Access to Medicine Foundation.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Trump Executive Order On Drug Pricing Is A Mixed Bag For Pharma

16 Apr 2025

• By Mandy Jackson

The order aims to eliminate the gap between small molecules and biologics in terms of the time to IRA-mandated Medicare negotiations, but pharma’s gain could be offset by other directives.

Compounding Unlikely To Solve GLP-1 Affordable Access Issues

10 Apr 2025

• By Alaric DeArment

The end of semaglutide and tirzepatide shortages means large-scale compounding is declining, ICER noted. But compounded versions – and the demand for them – are likely here to stay.

Multiple Tactics Likely Needed To Control Obesity Drug Costs

09 Apr 2025

• By Alaric DeArment

ICER’s new white paper pointed to estimates that the GLP-1 drugs may result in more than $100bn in annual spending, highlighting the need to rein in costs.

Mounjaro In India: Price Differential, Window Of Opportunity

25 Mar 2025

• By Anju Ghangurde

Lilly’s Mounjaro arrives in India, with the 2.5mg vial priced at under $41 in a market that has over 100 million diabetics and increasing obesity rates. Will the product see sharp demand like in China, carving out a chunk of the pie ahead of the potential arrival of semaglutide generics and could there be concerns of ‘suitcase' exports?